

# Alberto Puccini

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3588973/alberto-puccini-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

80 papers	1,245 citations	16 h-index	35 g-index
89 ext. papers	1,915 ext. citations	5.8 avg, IF	4.66 L-index

#	Paper	IF	Citations
80	Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	1
79	Landscape of , Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in -Mutated Cancers.. <i>JCO Precision Oncology</i> , <b>2022</b> , 6, e2100245	3.6	2
78	Targeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical Perspectives. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 662055	5.3	3
77	Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. <i>Npj Precision Oncology</i> , <b>2021</b> , 5, 95	9.8	1
76	Microsatellite-Instability-High Advanced Colorectal Cancer. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 971-972	59.2	0
75	Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients. <i>Scientific Reports</i> , <b>2021</b> , 11, 12191	4.9	0
74	Impact of Sociodemographic Disparities and Insurance Status on Survival of Patients with Early-Onset Colorectal Cancer. <i>Oncologist</i> , <b>2021</b> , 26, e1730-e1741	5.7	1
73	Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies <b>2020</b> , 8,		15
72	-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype. <i>Cancers</i> , <b>2020</b> , 12,	6.6	7
71	Redefining Colorectal Cancer by Tumor Biology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2020</b> , 40, 1-13	7.1	3
70	Molecular profile of BRCA-mutated biliary tract cancers. <i>ESMO Open</i> , <b>2020</b> , 5, e000682	6	34
69	Metastatic sarcoma: tailored strategies for a heterogeneous disease. <i>Memo - Magazine of European Medical Oncology</i> , <b>2020</b> , 13, 179-184	0.3	0
68	A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. <i>European Journal of Cancer</i> , <b>2020</b> , 131, 89-97	7.5	3
67	Comprehensive molecular profiling of IDH1/2 mutant biliary cancers (BC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 479-479	2.2	6
66	Variation in genetic polymorphisms and gene expression of HLA-E to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI/cetuximab: Data from the phase III FIRE-3 trial.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 245-245	2.2	0
65	Polymorphisms of genes encoding for regulatory proteins in the coagulation cascade to predict outcome for stage II and III colon cancer.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 227-227	2.2	
64	Genetic variants in R-Spondin/RNF43 complex and gene expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 190-190	2.2	

63	Comprehensive gene expression analysis of IDH1/2 mutant biliary cancers (BC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4598-4598	2.2	
62	Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer. <i>Oncologist</i> , <b>2020</b> , 25, 404-413	5.7	13
61	The impact of ARID1A mutation on molecular characteristics in colorectal cancer. <i>European Journal of Cancer</i> , <b>2020</b> , 140, 119-129	7.5	13
60	A new prognostic and predictive tool for shared decision making in stage III colon cancer. <i>European Journal of Cancer</i> , <b>2020</b> , 138, 182-188	7.5	7
59	Molecular characteristics of and mutations in pancreatic ductal adenocarcinoma. <i>ESMO Open</i> , <b>2020</b> , 5, e000942	6	11
58	Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5943-5951	12.9	17
57	Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 2948-2956	7.5	32
56	Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 3096-3103	12.9	30
55	Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. <i>European Journal of Cancer</i> , <b>2019</b> , 111, 138-147	7.5	3
54	AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3. <i>International Journal of Cancer</i> , <b>2019</b> , 145, 2082-2090	7.5	0
53	Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. <i>Oncologist</i> , <b>2019</b> , 24, 319-326	5.7	19
52	The impact of panitumumab treatment on survival and quality of life in patients with wild-type metastatic colorectal cancer. <i>Cancer Management and Research</i> , <b>2019</b> , 11, 5911-5924	3.6	15
51	Maintenance Olaparib for Metastatic Pancreatic Cancer. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1491	59.2	4
50	BRCA1 genetic variant to predict survival in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI/bevacizumab (bev): Results from phase III TRIBE and FIRE-3 trials.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3145-3145	2.2	2
49	Molecular landscape of colorectal cancers harboring R-spondin fusions.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3588-3588	2.2	3
48	Gene mutations of SWI/SNF complex and molecular profile in colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3600-3600	2.2	1
47	Frequency of BRCA mutation in biliary tract cancer and its correlation with tumor mutational burden (TMB) and microsatellite instability (MSI).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4085-4085	2.2	8
46	Association of BRCA-mutant pancreatic cancer with high tumor mutational burden (TMB) and higher PD-L1 expression.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4133-4133	2.2	8

45	Characteristics of colorectal cancer (CRC) patients with BRCA1 and BRCA2 mutations.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 606-606	2.2	3
44	Th17 cell pathway-related genetic variants in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC, and FIRE-3.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 594-594	2.2	
43	Genetic variants in the lipopolysaccharide (LPS) receptor complex and TLR4 expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 564-564	2.2	
42	Polymorphisms in the telomerase complex to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 566-566	2.2	
41	Streamlining universal screening for lynch syndrome (LS): Towards improved yield of genetic counseling (GC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 503-503	2.2	
40	Genetic variations within the CD40L immune stimulating gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab: Data from FIRE-3 and TRIBE.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 558-558	2.2	
39	Comprehensive molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 63-63	2.2	
38	Gene expression and genetic variants in ParkinsonWdisease (PD) genes to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3 phase III trial.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3595-3595	2.2	0
37	Molecular differences between lymph nodes (LNs) and distant metastases (mets) in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3130-3130	2.2	
36	Polymorphisms in the dopamine (DA) signaling to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE, MAVERICC, and FIRE-3 phase III trials.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3048-3048	2.2	0
35	Association of genetic variations within the T-cell costimulatory LIGHT gene with outcome in stage II and III colon cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2633-2633	2.2	
34	Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, e8-e19	3.8	9
33	Safety and Tolerability of c-MET Inhibitors in Cancer. <i>Drug Safety</i> , <b>2019</b> , 42, 211-233	5.1	40
32	B cell and B cell-related pathways for novel cancer treatments. <i>Cancer Treatment Reviews</i> , <b>2019</b> , 73, 10-19	14.4	59
31	Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. <i>Molecular Cancer Research</i> , <b>2018</b> , 16, 805-812	6.6	114
30	Outlooks on Epstein-Barr virus associated gastric cancer. <i>Cancer Treatment Reviews</i> , <b>2018</b> , 66, 15-22	14.4	74
29	The role of tumor angiogenesis as a therapeutic target in colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2018</b> , 18, 251-266	3.5	29
28	Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. <i>Cancer Cell International</i> , <b>2018</b> , 18, 99	6.4	34

27	Molecular Variances Between Right- and Left-sided Colon Cancers. <i>Current Colorectal Cancer Reports</i> , <b>2018</b> , 14, 152-158	1	3
26	Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma. <i>Oncologist</i> , <b>2018</b> , 23, 1319-1327	5.7	61
25	Young Patients with Colorectal Cancer: Risk, Screening, and Treatment. <i>Current Colorectal Cancer Reports</i> , <b>2018</b> , 14, 159-165	1	1
24	Association Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3 Study. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, 215-222.e3	3.8	3
23	Circadian clock gene PER1 mutations in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 12106-12106	2.2	2
22	Polymorphism in the circadian clock pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3576-3576	2.2	1
21	Polymorphism in cancer-associated fibroblasts (CAFs) related genes and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) enrolled in two independent randomized phase III trials: TRIBE and FIRE-3.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 645-645	2.2	1
20	Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives. <i>Journal of Cancer Metastasis and Treatment</i> , <b>2018</b> , 4,	3.8	2
19	Association of genetic variations within the PD-L2 immune checkpoint gene with outcome in stage II and III colon cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 626-626	2.2	
18	Molecular characterization of intestinal (IS) and diffuse subtypes (DS) of gastric adenocarcinomas.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 60-60	2.2	
17	The impact of Tfh cell/ B cell pathway-related genetic variants in metastatic colorectal cancer patients with bevacizumab-based chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 651-651	2.2	
16	Polymorphisms in beta-defensin pathways and clinical outcomes in metastatic colorectal cancer patients treated with FOLFIRI-bevacizumab in two randomized phase III trials.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 662-662	2.2	
15	Genetic variants in methylation and demethylation pathways to predict clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI/Bev: Data from TRIBE and FIRE-3 trials.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 646-646	2.2	
14	Genetic variants within the glucocorticoids related genes to predict outcome in patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 12098-12098	2.2	
13	Molecular analyses of left- and right-sided tumors in adolescents and young adults (AYA) with colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3577-3577	2.2	
12	Molecular characterization of appendiceal cancer and comparison with right-sided (R-CRC) and left-sided colorectal cancer (L-CRC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3611-3611	2.2	
11	Comprehensive genomic profiling of 724 gastroenteropancreatic neuroendocrine tumors (GEP-NETs).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 4098-4098	2.2	
10	Genetic variations in the 2M/HLA-E immunomodulatory complex to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line FOLFIRI/Cetuximab: Data from the phase III FIRE-3 trial.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 12107-12107	2.2	

9	The impact of Th17 cell pathway-related genetic variants in metastatic colorectal cancer patients treated with bevacizumab-based chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e15578-e15578 <sup>2.2</sup>		
8	CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. <i>Cancer Treatment Reviews</i> , <b>2018</b> , 63, 40-47	14.4	433
7	A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 784-793	12.9	14
6	Colorectal cancer in 2017: Practice-changing updates in the adjuvant and metastatic setting. <i>Nature Reviews Clinical Oncology</i> , <b>2018</b> , 15, 77-78	19.4	20
5	Comparative molecular analysis between microsatellite instability-high (MSI-H) tumors with high tumor mutational burden (TMB-H) versus MSI-H tumors with TMB-intermediate/low. <i>Annals of Oncology</i> , <b>2018</b> , 29, viii650-viii651	10.3	4
4	Management of Advanced Small Bowel Cancer. <i>Current Treatment Options in Oncology</i> , <b>2018</b> , 19, 69	5.4	8
3	What We Know About Stage II and III Colon Cancer: It's Still Not Enough. <i>Targeted Oncology</i> , <b>2017</b> , 12, 265-275	5	21
2	Colorectal cancer: epigenetic alterations and their clinical implications. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>2017</b> , 1868, 439-448	11.2	35
1	The urgent need to improve the tools to assess clinical benefit and value of cancer treatment. <i>European Journal of Cancer</i> , <b>2017</b> , 83, 324-328	7.5	8